|
| ||||||||||||||
Examine The CNS Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities LONDON, UNITED KINGDOM--(MARKET WIRE)--Oct 9, 2008 -- Reportlinker.com announces that a new market research report
related to the Pharmaceutical industry is available in its
catalogue. The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities The CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. High levels of investment have contributued to a rich product pipeline, with an estimated 600 clinical candidates currently under development, and companies are widely engaged in licensing novel/clinically differentiated CNS products. The sector has struggled recently however, with previously dominant product classes coming under increasing pressure from generic competition and safety concerns. 'The CNS Market Outlook to 2013' is a new report published by Business Insights that provides comprehensive coverage of the major markets within the global CNS disorders market, incorporating a detailed epidemiological analysis of major indications and key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment within each indication are assessed and ten of the market's leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided. Discover the key trends and growth drivers of the CNS market, assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products with this new report. Table of Contents The CNS Market Outlook to 2013 Executive Summary 14 Overview and epidemiology of CNS disorders 14 Global market analysis 14 Pipeline analysis 15 Competitive landscape 16 Chapter 1 Scope and methodology 20 Scope 20 Methodology 21 Chapter 2 Overview and epidemiology of CNS disorders 24 Summary 24 Introduction 25 Schizophrenia 28 Overview 28 Epidemiology 30 Forecast epidemiology 31 Major depressive disorder 32 Overview 32 Epidemiology 35 Forecast epidemiology 36 Epilepsy 37 Overview 37 Epidemiology 38 Forecast epidemiology 39 Alzheimer's disease 40 Overview 40 Epidemiology 43 Forecast epidemiology 44 iv Insomnia 46 Overview 46 Epidemiology 47 Epidemiology 47 Parkinson's disease 47 Overview 47 Epidemiology 48 Forecast epidemiology 50 Migraine 51 Overview 51 Epidemiology 53 Forecast epidemiology 53 Attention-deficit hyperactivity disorder 54 Overview 54 Epidemiology 56 Chapter 3 Global market analysis 58 Summary 58 Introduction 59 Market analysis by country 59 Licensing trends 60 Market analysis by indication 61 Leading brand dynamics 63 Key events in the CNS disorder market 64 Launch of first transdermal patch formulation of Novartis' Exelon for the treatment of AD 64 Once-Daily and long acting stimulants remain the gold standard in the treatment of ADHD 65 Disappointing clinical results from bapineuzumab 65 Recall of Neupro in the US due to manufacturing problems 65 Spheramine fails to demonstrate efficacy in Phase IIb Parkinson's disease study 66 GLP-1 may treat Parkinson's disease 66 Acetyl cholinesterase inhibitors to remain the mainstay treatment option for AD 67 Newer therapies in epilepsy prove efficacious in multiple CNS disorder indications 67 FDA orders warning labels for antipsychotic drugs 67 Newer agents continue to dominate antipsychotic market 67 Label expansions for SSRIs provides an opportunity for growth and differentiation 68 Schizophrenia 68 Market analysis 68 Leading brands in the schizophrenia market 70 v Atypical antipsychotics 71 Key brand analysis 71 Schizophrenia sales forecast to 2013 76 Major depressive disorder (MDD) 77 Market analysis 77 Leading brands in the antidepressants market 78 Selective Serotonin Reuptake inhibitors 79 Market Dynamics 80 Key brand analysis 80 Selective Norepinephrine Reuptake Inhibitors 82 Market Dynamics 82 Key brand analysis 83 Antidepressants sales forecast to 2013 85 Epilepsy 86 Market analysis 86 Leading brands in the anti-epileptic market 87 Second generation anti-epileptics 88 Key brand analysis 88 Anti-epilepsy sales forecast to 2013 92 Alzheimer's disease 93 Market analysis 93 Leading brands in the anti-Alzheimer's market 94 Cholinesterase inhibitors market analysis 95 Market analysis 95 Key brand analysis 96 NMDA receptor antagonists market analysis 98 Key brand analysis 98 Anti-Alzheimer's sales forecast to 2013 100 Insomnia 101 Market analysis 101 Non-benzodiazepines 103 Key brand analysis 103 Anti-insomnia sales forecast to 2013 106 Parkinson's disease (PD) 107 Market analysis 107 Leading brands in the anti-parkinson's market 108 COMT inhibitors 109 Key brand analysis 109 Dopamine agonists 110 Key brand analysis 110 Mono-amino oxidase (MAO) inhibitors 111 Key brand analysis 111 Anti-parkinson's sales forecast to 2013 112 Migraine 113 Market analysis 113 Leading brands in the anti-migraine market 114 Triptans 115 Key brand analysis 115 Anti-migraine sales forecast to 2013 118 vi Attention-deficit hyperactivity disorder (ADHD) 119 Market analysis 119 Leading brands in the ADHD market 120 Stimulants 121 Key brand analysis 121 Non-stimulants 122 Key brand analysis 122 ADHD sales forecast to 2013 123 Total CNS disorders' sales forecast 124 Chapter 4 Pipeline analysis 128 Summary 128 Introduction 129 Key trends in R & D 130 Disease modifying agents hold promise in AD 131 Novel drugs with differentiated profiles represent a sizeable market opportunity 131 New drug delivery formulations confer a competitive advantage 132 Combination drugs demonstrate advantages over individual components 132 CNS disorders pipeline 133 Leading drugs in development 136 Profiles of key pipeline products 137 Recently marketed drugs 137 Invega 137 Pristiq 140 Treximet 142 Vyvanse 144 Drugs in registration 146 Asenapine 146 Inovelon 148 Paliperidone Palmitate 149 Vimpat 151 Drugs in phase III clinical studies 152 Almorexant (ACT-078573) 152 Amibegron (SR-58611) 154 Bapineuzumab (AAB-001) 156 Eplivanserin (SR-46349) 158 Saredutant (SR-48968) 160 Semagacestat (LY-450139) 161 Telcagepant (MK-0974) 163 Pipeline forecast 166 vii Chapter 5 Competitive landscape 170 Summary 170 Introduction 171 Sales performance of leading players 171 Detailed analysis of leading CNS players 178 Johnson & Johnson (J&J) 178 Overview 178 Sales focus by drug class 179 Marketed product portfolio 180 R&D pipeline analysis 181 Strategic and growth analysis 182 Eli Lilly 183 Overview 183 Sales focus by drug class 184 Marketed product portfolio 185 Marketed product portfolio: Strattera 186 R&D pipeline analysis 186 Strategic and growth analysis 187 GlaxoSmithKline (GSK) 188 Overview 188 Sales focus by drug class 188 Marketed product portfolio 190 R&D pipeline analysis 191 Strategic and growth analysis 192 Pfizer 193 Overview 193 Sales focus by drug class 193 Marketed product portfolio 194 R&D pipeline analysis 195 Strategic and growth analysis 197 AstraZeneca 198 Overview 198 Sales focus by drug class 198 Marketed product portfolio 200 R&D pipeline analysis 201 Strategic and growth analysis 202 Novartis 203 Overview 203 Sales focus by drug class 203 Marketed product portfolio 204 R&D pipeline analysis 205 Strategic and growth analysis 206 Sanofi-Aventis 207 Overview 207 Sales focus by drug class 207 Marketed product portfolio 208 R&D pipeline analysis 209 Strategic and growth analysis 211 viii Wyeth 211 Overview 211 Sales focus by drug class 211 Marketed product portfolio 213 R&D pipeline analysis 213 Strategic and growth analysis 214 Forest 215 Overview 215 Sales focus by drug class 216 Marketed product portfolio 217 R&D pipeline analysis 217 Strategic and growth analysis 219 Eisai 219 Overview 219 Sales focus by drug class 219 Marketed product portfolio 221 R&D pipeline analysis 221 Strategic and growth analysis 222 Chapter 6 Appendix 226 IMS Data 226 N2C - Anti-Migraine preparations 226 N3A - Anti-Epileptics 226 N4A - Anti-Parkinson drugs 226 N5A - Antipsychotics 226 N5B - Hypnotics/Sedatives 226 N6A - Antidepressants 226 N6B - Psychostimulants 226 N7D - Anti-Alzheimer's products 226 N7X - Other CNS drugs 226 Glossary 227 AD Assessment Scale cognition; (ADAS-cog) 227 ADHD-RS 227 Clinical Dementia Rating (CDR) scale 227 HAM-D17 227 Mini Mental State Exam (MMSE) 227 Neuropsychological Test Battery (NTB) 227 Personal and Social Performance Scale (PSP) 228 Positive and Negative Syndrome Scale for schizophrenia (PANSS) 228 List of Figures Figure 2.1: Schizophrenia: classification of symptoms 29 Figure 2.2: Typical treatment patterns in the treatment of schizophrenia 30 ix Figure 2.3: Different forms of epilepsy 37 Figure 2.4: Different stages of Alzheimer's disease 42 Figure 2.5: Typical treatment patterns in the treatment of Alzheimer's disease 43 Figure 2.6: Typical treatment patterns in the treatment of migraine 52 Figure 3.7: Global CNS market share by geography, 2007 59 Figure 3.8: Sales of types of CNS disorder brands, 2006-2007 60 Figure 4.9: Key trends in the R&D of CNS disorders, 2008 130 Figure 4.10: Leading recently launched products and late-stage R&D compounds indicated for the treatment of CNS disorders, 2008 136 Figure 5.11: Market share of key players by sales value, 2007 173 Figure 5.12: Projected market share of key players by sales value, 2013 175 Figure 5.13: Market share and ranking of leading players in the global CNS disorders market, 2007-2013 176 Figure 5.14: J&J's CNS portfolio sales by indication, 2007 179 Figure 5.15: Eli Lilly's CNS portfolio sales by indication, 2007 184 Figure 5.16: GSK's CNS portfolio sales by indication, 2007 189 Figure 5.17: Pfizer's CNS portfolio sales by indication, 2007 194 Figure 5.18: AstraZeneca's portfolio sales by indication, 2007 199 Figure 5.19: Novartis' portfolio sales by indication, 2007 203 Figure 5.20: Sanofi-Aventis' portfolio sales by indication, 2007 207 Figure 5.21: Wyeth's portfolio sales by indication, 2007 212 Figure 5.22: Forest's portfolio sales by indication, 2007 216 Figure 5.23: Eisai's portfolio sales by indication, 2007 220 x List of Tables Table 2.1: Estimated prevalence of CNS disorders across the seven major 27 Table 2.2: Estimated prevalence of schizophrenia across the seven major markets, 2007 31 Table 2.3: Forecast epidemiology of schizophrenia across the seven major markets, 2007-2013 32 Table 2.4: Estimated prevalence of MDD across the seven major markets, 2007 35 Table 2.5: Estimated prevalence of MDD across the seven major markets, 2007 36 Table 2.6: Estimated prevalence of epilepsy across the seven major markets, 2007 39 Table 2.7: Forecast epidemiology of epilepsy across the seven major markets, 2007-2013 40 Table 2.8: Estimated prevalence of Alzheimer's disease across the seven major markets, 2007 44 Table 2.9: Forecast epidemiology of AD across the seven major markets, 2007-2013 45 Table 2.10: Estimated prevalence of insomnia across the seven major markets, 2007 47 Table 2.11: Estimated prevalence of Parkinson's disease across the seven major markets, 2007 49 Table 2.12: Estimated prevalence of Parkinson's disease across the seven major markets, 2007 50 Table 2.13: Estimated prevalence of migraine across the seven major markets, 2007 53 Table 2.14: Forecast epidemiology of migraine across the seven major markets, 2007-2013 54 Table 2.15: Estimated prevalence of ADHD in adults across the seven major markets, 2008 56 Table 2.16: Estimated prevalence of ADHD in children across the seven major markets, 2008 56 Table 3.17: Breakdown of the global CNS market by drug class, $m, 2006-2007 61 Table 3.18: Leading brands in the global CNS market, $m, 2006-2007 63 Table 3.19: Breakdown of the global schizophrenia market by drug class, $m, 2006-2007 69 Table 3.20: Leading antipsychotic medications in the CNS market, $m, 2006-2007 70 Table 3.21: Antipsychotic products sales forecast, $m, 2007-2013 76 Table 3.22: Breakdown of the global antidepressant market by drug class, $m, 2006-2007 77 Table 3.23: Leading antipsychotic medications in the CNS market, $m, 2006-2007 78 Table 3.24: Leading SSRIs in the MDD market, $m, 2006-2007 80 Table 3.25: Leading SNRIs in the MDD market, $m, 2006-2007 82 Table 3.26: Antidepressants sales forecast, $m, 2007-2013 85 Table 3.27: Global epilepsy market, $m, 2006-2007 86 Table 3.28: Leading anti-epileptic medications in the CNS market, $m, 2006-2007 87 Table 3.29: Anti-epileptics sales forecast, $m, 2007-2013 92 Table 3.30: Breakdown of the global anti-alzheimer's market by drug class, $m, 2006-2007 93 Table 3.31: Leading anti-alzheimer drugs in the global CNS market by drug class, $m, 2006-2007 94 Table 3.32: Leading cholinesterase inhibitors in the global anti-alzheimer's market by drug class, $m, 2006-2007 95 Table 3.33: Leading NMDA receptor antagonists in the global anti-alzheimer's market by drug class, $m, 2006-2007 98 Table 3.34: Anti-alzheimer's products sales forecast, $m, 2007-2013 100 Table 3.35: Breakdown of the global insomnia market by drug class, $m, 2006-2007 101 Table 3.36: Leading insomnia drugs in the global CNS market by drug class, $m, 2006-2007 102 Table 3.37: Anti-insomnia products sales forecast, $m, 2007-2013 106 Table 3.38: Global anti-parkinson's disease market, $m, 2006-2007 107 Table 3.39: Leading anti-parkinson drugs in the global CNS market by drug class, $m, 2006-2007 108 Table 3.40: Anti-parkinson drugs sales forecast, $m, 2007-2013 112 Table 3.41: Breakdown of the global anti-migraine market by drug class, $m, 2006-2007 113 Table 3.42: Leading anti-migraine medications in the CNS market, $m, 2006-2007 114 xi Table 3.43: Anti-migraine products sales forecast, $m, 2007-2013 118 Table 3.44: Breakdown of the global ADHD market by drug class, $m, 2006-2007 119 Table 3.45: Leading ADHD medications in the CNS market, $m, 2006-2007 120 Table 3.46: Anti-ADHD products sales forecast, $m, 2007-2013 123 Table 3.47: CNS Market sales forecast by drug class, $m, 2007-2013 124 Table 4.48: CNS pipeline by indication and stage of development, 1H2008 133 Table 4.49: An overview of Invega 137 Table 4.50: An overview of Pristiq 140 Table 4.51: An overview of Treximet 142 Table 4.52: An overview of Vyvanse 144 Table 4.53: An overview of Asenapine 146 Table 4.54: An overview of Inovelon 148 Table 4.55: An overview of Paliperidone Palmitate 149 Table 4.56: An overview of Vimpat 151 Table 4.57: An overview of Almorexant (ACT-078573) 152 Table 4.58: An overview of Amibegron (SR-58611) 154 Table 4.59: An overview of Bapineuzumab (AAB-001) 156 Table 4.60: An overview of Eplivanserin (SR-46349) 158 Table 4.61: An overview of Saredutant (SR-48968) 160 Table 4.62: An overview of Semagacestat (LY-450139) 161 Table 4.63: An overview of Telcagepant (MK-0974) 163 Table 4.64: CNS disorders pipeline forecast, 2008-2013 ($m) 166 Table 5.65: Leading players in the global CNS disorders market, 2007-2013 ($m) 171 Table 5.66: J&J's CNS product portfolio, 2006-2007 180 Table 5.67: J&J's CNS R&D product pipeline, 2007 182 Table 5.68: Eli Lilly's CNS product portfolio, 2006-2007 185 Table 5.69: Eli Lilly's CNS R&D product pipeline, 2007 187 Table 5.70: GSK's CNS product portfolio, 2006-2007 190 Table 5.71: GSK's CNS R&D product pipeline, 2007 192 Table 5.72: Pfizer's CNS product portfolio, 2006-2007 194 Table 5.73: Pfizer's CNS R&D product pipeline, 2007 197 Table 5.74: AstraZeneca's CNS product portfolio, 2006-2007 200 Table 5.75: AstraZeneca's CNS R&D product pipeline, 2007 202 Table 5.76: Novartis' CNS product portfolio, 2006-2007 204 Table 5.77: Novartis' CNS R&D product pipeline, 2007 206 Table 5.78: Sanofi-Aventis' CNS product portfolio, 2006-2007 208 Table 5.79: Sanofi-Aventis' CNS R&D product pipeline, 2007 210 Table 5.80: Wyeth's CNS product portfolio, 2006-2007 213 Table 5.81: Wyeth's CNS R&D product pipeline, 2007 214 Table 5.82: Forest's CNS product portfolio, 2006-2007 217 Table 5.83: Forests' CNS R&D product pipeline, 2007 218 Table 5.84: Eisai's CNS product portfolio, 2006-2007 221 Table 5.85: Eisai's CNS R&D product pipeline, 2007 222 12 To order this report: The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities Contact: Contacts:
Reportlinker.com
Nicolas
US: (805) 652-2626 or Intl: +1-805-652-2626
Email: nbo@reportlinker.com
Source: Reportlinker.com
|  | |||||||||||||
